Riding recent momentum in the Duchenne muscular dystrophy space, Capricor Therapeutics, Wave Life Sciences, Regenxbio and ...

Despite mixed results using gene therapies to treat Duchenne muscular dystrophy, drug developers are pushing ahead with the ...

BOSTON - PepGen Inc. (NASDAQ: PEPG), a biotechnology firm focused on oligonucleotide therapies for severe neuromuscular and neurological diseases, is progressing with its CONNECT clinical program for ...

Sarepta Therapeutics unveiled new results from the second part of a clinical trial for its Duchenne muscular dystrophy gene ...

Roche has reported positive topline outcomes from the second year of the multinational Phase III EMBARK trial of Elevidys for ...

The gene therapy improved motor functions in children with Duchenne muscular dystrophy two years after treatment ...

The western portion of Georgia Street in downtown Indianapolis will close until 2026 for a redesign project, according to the Department of Metropolitan Development (DMD). The Georgia street redesign ...

While the last decade has brought considerable progress for patients with DMD, substantial unmet need remains. Several ...

The gene therapy delandistrogene moxeparvovec-rokl showed clinically meaningful benefits and disease stabilization at 2 years ...

Prophylactic cardiac treatment may prolong survival in Duchenne muscular dystrophy (DMD), but only one-quarter of individuals ...

Swiss biotech Santhera Pharmaceuticals has started launch preparations for its Duchenne muscular dystrophy (DMD) drug Agamree (vamorolone) in the UK, following a recommendation from England’s price ...

According to Dr Ann Agnes Mathew, Consultant Pediatric Neurologist at Bangalore Baptist Hospital, DMD is life-threatening and ...